Fig. 2
LD-RT significantly reduces amyloid load in pre-symptomatic TgAD rats. Concentration in Aβ40 (a; two-way-ANOVA: F(1,37) = 11.40, P < 0.01 for the main effect of group) or Aβ42 (b; two-way-ANOVA: F(1,34) = 8.681, P < 0.01 for the main effect of group) in hippocampus homogenates lysed into a Triton-X100 (Tx) buffer and analyzed by ELISA. Concentration in Aβ40 (c; Two-way-ANOVA: F(1,37) = 19.73, P = 0 < 0.0001 for the main effect of group) or Aβ42 (d; two-way-ANOVA: F(1,37) = 14.00, P < 0.001 for the main effect of group) in the guanidine (Gua)-soluble fraction. Concentration in Aβoligomers (e; two-way-ANOVA: F(1,35) = 11.09, P < 0.01 for the main effect of group) measured in hippocampus homogenates lysed into a Triton-X100 (Tx) buffer. Two-way ANOVA (group, hemisphere as between factors). Concentrations in Aβ40 (f; t(18) = 2.094, P = 0.0507) or Aβ42 (g) in the plasma (unpaired t-test). Soluble APPα (h; Kruskal–Wallis, P < 0.01; Dunn’s comparison) and APPβ (i) levels quantified by ELISA in the frontal cortex. Data are normalized to the weight of tissue of the frontal cortex. **P < 0.01, ***P < 0.001. Hipp: hippocampus; mo: months; Gy: Gray, L: left hemisphere; R: right hemisphere